HomeFilePharmacology

Pharmacology

View Category

Antithrombotic Anticoagulants

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard...
solaci -
Learn More
Antiplatelet

ACC 2021 | ADAPTABLE: Low Doses of Aspirin Are Equally Effective and Present Lower Bleeding Risk

Patients diagnosed with cardiovascular disease taking aspirin as secondary prevention can take lower doses and achieve the...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | TALOS-AMI: De-escalating from Ticagrelor to Clopidogrel after One Month

After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when...
solaci -
Learn More
Other

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in...
solaci -
Learn More
Antiplatelet

Single or Dual Antiplatelet Therapy in Stroke or Transient Ischemic Attack?

Antiplatelet therapy is key to prevent thrombotic events after a transient ischemic attack (TIA) or ischemic stroke....
solaci -
Learn More
Antiplatelet

How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician...
solaci -
Learn More
Acute coronary syndromes

Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight

Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to...
solaci -
Learn More